


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 05524-003001	Application No. 10/629,045
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant David Potter	
(37 CFR §1.98(b))		Filing Date July 28, 2003	Group Art Unit 1642-1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						


Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	AC						
	AD						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
NAR	AE	Andre, Patrice, et al., "An Inhibitor of HIV-1 Protease Modulates Proteasome Activity, Antigen Presentation, and T Cell Responses," <i>Proc. National Acadamy Science USA</i> , Vol. 95: 13120-13124 (1998).
NAR	AF	Carragher, N. O., et al., "v-Src-Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Transformation," <i>Molecular and Cellular Biology</i> , p. 257-269 (2002).
NAR	AG	Fenteany, Gabriel, et al., "Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine Modification by Lactacystin," <i>Science</i> , Vol. 268, No. 5211: 726-731 (1995).
NAR	AH	Gaedicke, Simone, et al., "Antitumor Effect of the Human Immunodeficiency Virus Protease Inhibitor Ritonavir: Induction of Tumor-Cell Apoptosis Associated with Perturbation of Proteasomal Proteolysis," <i>Cancer Research</i> , Vol. 62: 6901-6908 (2002).
NAR	AI	Glading, Angela, et al., "Membrane Proximal ERK Signaling is Required for M-calpain Activation Downstream of Epidermal Growth Factor Receptor Signaling," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 26: 23341-23348 (2001).
LAR	AJ	Hehner, Steffen, P., et al., "The Antiinflammatory Sesquiterpene Lactone Parthenolide Inhibits NF- κ B by Targeting the I κ B Kinase Complex," <i>The American Association of Immunologists</i> , Vol. 163: 5617-5623 (1999).
NAR	AK	Holmes-McNary, Minni, et al., "Chemopreventive Properties of <i>trans</i> -Resveratrol are Associated with Inhibition of Activation of the I κ B Kinase," <i>Cancer Research</i> , Vol. 60: 3477-3483 (2000).
WAL	AL	Kubbutat, Michael H.G., "Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability," <i>Molecular and Cellular Biology</i> p. 460-468 (1997).
NAR	AM	Liu, Catherine H., et al. "Overexpression of Cyclooxygenase-2 is Sufficient to Induce Tumorigenesis in Transgenic Mice," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 21: 18563-18569 (2001).
LAR	AN	Pati, Shibani, et al. "Antitumorigenic Effects of HIVProtease Inhibitor Ritonavir: Inhibition of Kaposi Sarcoma," <i>The American Society of Hematology</i> , Vol. 99, No. 10: 3771-3779 (2002).
NAR	AO	Ross, T. Douglas, et al., "Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines," <i>Nature Genetics</i> , Vol. 24: 227-235 (2000).

Examiner Signature 	Date Considered 06 DECEMBER 2005
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 05524-003001	Application No. 10/629,045
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Potter	
		Filing Date July 28, 2003	Group Art Unit 1642 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
NAR	AP	Shiba, Eiichi, et al., "Mechanism of Growth Inhibition by Calpain Inhibitor in MCF-7 Cells," <i>Anticancer Research</i> , Vol. 17: 1919-1924 (1997).
NAR	AQ	Shiba, Eiichi, et al., "Possible Involvement of Calpain in the Growth of Estrogen Receptor Positive Breast Cancer Cells," <i>Anticancer Research</i> Vol. 16: 773-778 (1996).
LAR	AR	Schoenwaelder, Simone M., et al., "Evidence for a Calpeptin-sensitive Protein-tyrosine Phosphatase Upstream of the Small GTPase Rho," <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 20: 14359-14367 (1999).

Examiner Signature	Date Considered
 David Potter	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 05524-003001	Application No. 10/629,045
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Potter	
		Filing Date July 28, 2003	Group Art Unit 1642 1b 14

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>DPP</i>	AA	6,294,518 B1	09/25/01	Potter, et al.			
<i>MAY 10 2004</i>	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	AL						
	AM						
	AN						
	AO						
	AP						

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	AQ						
	AR						
	AS						
	AT						

Examiner Signature <i>David Potter</i>	Date Considered <i>06 DECEMBER 2005</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	